 Home > Chemicals Industry > China Chemical > Biopharmaceutical industry chain: the problem of relying on imports of Chinese equipment is prominent

Biopharmaceutical industry chain: the problem of relying on imports of Chinese equipment is prominent

 Last Update: 2022-02-02
 Source: Internet
 Author: User

Tags

tma chemical

chemistry chemical equations

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

[ Chemical Machinery Equipment Network Market Analysis ] In recent years, the booming development trend of the biomedical industry has been unstoppable.
In 2019, the market size has exceeded 350 billion yuan.
But from the perspective of the biopharmaceutical industry chain, there are still weak links.
Among them, in the upstream, the problem of relying on imports of Chinese equipment is prominent, and it is urgent to break the bottleneck of being restricted by people.

Chemical machinery and equipment network market analysis chemical machinery and equipment

The biopharmaceutical industry is developing rapidly

The market size will reach 400 billion yuan

　　In recent years, with the development of my country’s economy, the change of people’s health concepts, the acceleration of the aging process, the continuous upgrade of consumption levels, and the introduction of a series of favorable policies to encourage and support the biopharmaceutical industry, my country’s biopharmaceutical industry is gaining momentum.
Rapidly, the market scale continues to expand.
According to statistics, in 2018, the market size of my country's biomedical industry exceeded 350 billion yuan, and it is expected that by 2020, this market space will reach 400 billion yuan.

　　The Science and Technology Innovation Board has innovated the listing system and provided a new financing path for unprofitable biopharmaceutical companies, which will further promote the development of the biomedical industry.
At the same time, new waves of investment in the domestic biopharmaceutical field have also continued to emerge.
For example, according to the position of US stocks at the end of the third quarter of 2020 announced by Hillhouse, among the 22 newly entered companies in the third quarter, the biopharmaceutical field Enterprises accounted for nearly half, and 10 companies were among them, which shows that institutions are "favoring" biomedical companies.

　　Under the influence of these favorable factors, the industry expects that the biopharmaceutical industry in 2021 will usher in further development space, and my country's biomedicine market will soon become the second largest biomedical market after the United States.

　　Weak links in the industry chain

　　China's equipment dependence on imports is prominent

　　Throughout the biopharmaceutical industry chain, the upstream pharmaceutical foundation is mainly composed of raw materials, pharmaceutical equipment and biotechnology; the middle stream is the R&D and production link of biopharmaceuticals; the downstream is mainly for the sales and consumption of pharmaceuticals.
Among them, biopharmaceutical equipment is a relatively weak link in the entire industry chain.

Pharmaceutical equipment

　　It is understood, biopharmaceutical equipment including a biological reactor , freezers, sterilization equipment and the like.
With the continuous development of the biopharmaceutical industry, these biopharmaceutical equipment has also become a common demand for biopharmaceutical companies.
But while seeing the opportunities, we also need to pay attention to the huge challenges facing the biopharmaceutical equipment industry.

reactor

　　As far as the domestic biopharmaceutical equipment market is concerned, most of the shares are occupied by European, American and Japanese companies.
The lack of market in domestic equipment is prominent, and the overall innovation capability of the industry is not high.
This also makes most domestic biopharmaceutical companies purchase equipment Most of them are imported equipment, which has a low degree of trust in domestic enterprises.

　　The industry pointed out that the cost of imported biopharmaceutical equipment is often very high, which also makes the biopharmaceutical equipment of domestic pharmaceutical companies subject to others.
In the context of the continuous development of the biopharmaceutical industry, domestic biopharmaceutical equipment companies need to increase their R&D efforts, break the "stuck neck" bottleneck, create cost-effective biopharmaceutical equipment for users, and meet the needs of pharmaceutical companies for high-quality production.

　　The author has also learned that many domestic biopharmaceutical equipment companies are currently making efforts in the middle field.
Take the bioreactor as an example.
This is a very core and critical equipment for biopharmaceuticals.
It plays an important role in the biopharmaceutical process.
It can produce high value-added compounds and drugs.
It is reported that in response to the low reliability and high energy consumption of domestic bioreactors, some companies have developed reliable, energy-saving, practical and beautiful bioreactor equipment by gathering domestic and foreign product design and manufacturing engineering and technical personnel.
And effectively improve the production efficiency of pharmaceutical companies.

　　Some analysts pointed out that traditional bioreactors still occupy a large proportion in the current pharmaceutical industry, and how to better improve traditional bioreactors is a challenge facing the current industry.
In this regard, some industry recommends to start with the analysis of the current status of the industry and future development trends, and then actively seek cooperation between enterprises to solve the pain points and difficulties in the industry.
Concentrate on the research and development of equipment and integrate new technologies and production concepts on the basis of traditional bioreactors to meet the needs of large-scale industrial production of various products, thereby helping the biopharmaceutical equipment industry to develop in a more diversified direction.

　　Original title: Weak links in the biopharmaceutical industry chain: China's equipment relies on imports to become prominent

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.